Mesoblast (MESO) to Release Quarterly Earnings on Wednesday

Key Points

• Mesoblast (NASDAQ:MESO) is set to announce its H2 2025 earnings on August 27th, with analysts predicting a loss of $0.20 per share and revenue of $7.481 million.
• Hedge funds have been active in acquiring shares of Mesoblast, with recent positions taken by Raymond James Financial, Creative Planning, and Goldman Sachs.
• Analyst sentiment on Mesoblast varies, with a consensus rating of "Buy" and an average target price of $18.00, despite recent downgrades from Jefferies Financial Group.

Mesoblast (NASDAQ:MESO - Get Free Report) will likely be posting its H2 2025 results before the market opens on Wednesday, August 27th. Analysts expect Mesoblast to post earnings of ($0.20) per share and revenue of $7.4810 million for the quarter. Individuals may visit the the company's upcoming H2 2025 earningresults page for the latest details on the call scheduled for Wednesday, September 10, 2025 at 6:00 PM ET.

Mesoblast Stock Performance

MESO stock traded up $0.64 during mid-day trading on Friday, reaching $15.81. The company had a trading volume of 162,232 shares, compared to its average volume of 151,117. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. The stock has a 50 day simple moving average of $13.38 and a two-hundred day simple moving average of $13.10. Mesoblast has a 52 week low of $6.00 and a 52 week high of $22.00.

Institutional Investors Weigh In On Mesoblast

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in Mesoblast during the 2nd quarter worth $86,000. Creative Planning bought a new stake in shares of Mesoblast in the 2nd quarter valued at about $141,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Mesoblast in the 1st quarter valued at about $3,209,000. Institutional investors own 1.43% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Jefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Canaccord Genuity Group raised Mesoblast to a "strong-buy" rating in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Mesoblast currently has a consensus rating of "Buy" and an average target price of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.